Larimar Therapeutics, Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Larimar Therapeutics, Inc. (LRMR)

If you purchased or acquired Larimar Therapeutics securities between December 2024 and September 2025, you may be eligible to join this securities investigation and seek compensation.

About Larimar Therapeutics

Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for rare diseases. Its lead product candidate, nomlabofusp, targets Friedreich’s ataxia, a serious and progressive neuromuscular disorder.

Over the past year, the company’s stock price has experienced significant volatility, especially in connection with clinical trial updates and regulatory milestones.

Potential Concerns Under Investigation

The investigation focuses on whether Larimar Therapeutics made misleading statements or omitted important information regarding the safety profile of nomlabofusp during its clinical development for Friedreich’s ataxia.

On December 16, 2024, the company issued a press release describing nomlabofusp as “generally well tolerated,” reporting only two serious adverse events that resolved within 24 hours. No mention was made of allergic reactions or other safety concerns.

Throughout the first half of 2025, Larimar allegedly highlighted the strength of its data package and stated it was “on track” to submit a Biologics License Application. These statements seemingly helped reinforce investor confidence in the company’s clinical and regulatory trajectory, supporting its market position ahead of planned milestones.

However, on September 29, 2025, before the market opened, Larimar disclosed for the first time that seven of 39 patients in the trial had experienced anaphylaxis. Despite the release being framed as “positive data,” this new information allegedly represented a significant shift from prior communications. Following the announcement, Larimar’s stock fell $1.72 per share, or 33.6%, closing at $3.38, and substantially harming investors.

Attorneys are reviewing whether Larimar’s earlier statements about nomlabofusp’s safety and regulatory outlook accurately reflected the known risks and whether investors were fully informed about the accumulating incidence of severe allergic reactions.

The investigation may also assess whether the company’s July 2025 $65.1 million stock offering or other capital-raising efforts created financial pressure to sustain optimism before revealing adverse events. Legal professionals are analyzing whether these circumstances influenced investor expectations and the timing of key disclosures.

Your Rights and Next Steps

Investors who purchased Larimar Therapeutics securities between December 2024 and September 2025, may have important legal rights. At this stage, this is an investigation, not a filed lawsuit. Attorneys are reviewing whether potential securities law violations occurred and whether investors may be eligible to recover losses.

If the investigation reveals evidence of misleading statements or material omissions, it could lead to a class action lawsuit seeking compensation for affected shareholders. Investors who join the investigation may have the opportunity to participate in any resulting class action and share in potential recoveries. Acting promptly is important, as securities investigations are time-sensitive and may have participation deadlines.

Investors are encouraged to organize documentation of their Larimar Therapeutics transactions during the relevant period, including purchase and sale records, account statements, and any relevant communications received from the company.

You May Be Entitled to Compensation

If you purchased Larimar Therapeutics securities and suffered losses during the relevant period, you may be entitled to compensation. Securities investigations move quickly, and there may be strict deadlines to join any future class action. Lawyers are ready to help evaluate your claim and guide you through the process.

To protect your rights and participate in the investigation, complete the form below.